Solriamfetol for the Management of Excessive Daytime Sleepiness

Cuomo, Megan C; Sheehan, Amy; Jordan, Joe K

doi:10.1177/08971900211009080

Cited by 3 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Solriamfetol has been shown to be generally safe and well-tolerated in clinical trials 29 . The most common adverse effects reported in clinical trials include headache, nausea, and decreased appetite 30 .…”

Section: Sodium Oxybatementioning

confidence: 99%

Therapeutical Interventions for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; A Review of Phase Iv Clinical Trials

Alorfi¹

2023

Bulletin of Pharmaceutical Sciences. Assiut

View full text Add to dashboard Cite

Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a disabling and complex illness with multifactorial etiology. Current clinical trials were examined to understand the characteristics of ME/CFS as well as possible therapeutical interventions. Aim: To identify features of clinical trials related to ME/CFS registered at ClinicalTrials.gov, specifically, the therapeutical interventions used to manage the syndrome in phase IV. Method: Analysis of all clinical trials registered at ClinicalTrials.gov for ME/CFS. Those clinical trials that employed a targeted therapy were included. The analysis identified a selection of clinical trials examining a targeted therapy for ME/CFS, providing a platform for further exploration of potential treatments. Results: By November 19th, 2022, 151 clinical trials related to ME/CFS had been found. Interventional studies were the most prevalent type. However, the trials were restricted to specific continents and were not extensively conducted in pediatric patients. Micronutrients were the most commonly used intervention. Phase IV studies had fewer clinical trials with limited interventional measures. Only three out of nine studies completed pharmacological interventional studies, and of these, sodium oxybate was being used most frequently. Conclusion: Among the clinical trials identified through this paper, there were few related to ME/CFS treatment. The interventions in the completed phase IV studies involved drugs that mainly interacted with the CNS, and more rarely that had an effect on blood vessels and blood perfusion. The limited number of phase IV clinical trials meant that the results were inconclusive.

show abstract

Section: Sodium Oxybatementioning

confidence: 99%

Therapeutical Interventions for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; A Review of Phase Iv Clinical Trials

Alorfi¹

2023

Bulletin of Pharmaceutical Sciences. Assiut

View full text Add to dashboard Cite

show abstract

“…Solriamfetol is a dopamine and noradrenaline reuptake inhibitor [ 12 ]. Solriamfetol does not have monoamine-relaxing properties, which explains why there is a lack of hypersonic when the drug is discontinued [ 11 ].…”

Section: Reviewmentioning

confidence: 99%

“…Solriamfetol does not have monoamine-relaxing properties, which explains why there is a lack of hypersonic when the drug is discontinued [ 11 ]. Solriamfetol is classified as a controlled substance class IV due to its abuse potential properties with doses over 300 mg [ 12 ]. Overall, in the four analyzed clinical trials, the drug was well tolerated and improved EDS in patients with narcolepsy regardless of whether they have cataplexy.…”

Section: Reviewmentioning

confidence: 99%

Solriamfetol for the Use of Narcolepsy: A Systematic Review

Iturburu¹,

Vela²,

Cruz³

et al. 2022

Cureus

View full text Add to dashboard Cite

Narcolepsy is a chronic and disabling neurological disorder characterized by excessive daytime sleepiness (EDS) and cataplexy. Historically, some medications have demonstrated efficacy in managing EDS and cataplexy symptoms. However, some patients cannot tolerate them, become refractory, or may use concomitant medications that preclude the use due to drug-drug interaction. Therefore, there is a necessity to explore the efficacy of new treatments, such as solriamfetol (JZP-110), a 2019 FDA-approved drug indicated to improve wakefulness in adults with EDS associated with narcolepsy. We conducted this systematic review to investigate the effectiveness of solriamfetol in EDS and cataplexy, and the drug's overall safety. For this study, we used the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and MOOSE protocol. After an initial search of 119 papers, we included four clinical trials to investigate and analyze the use of solriamfetol for the treatment of narcolepsy. Solriamfetol was proven to improve objective measures of EDS in all clinical trials. We conducted this systematic review using objective measures such as the Epworth Sleepiness Scale and the Maintenance of Wakefulness Test. Overall, cataplexy was not formally evaluated in the four clinical trials; however, it demonstrated that EDS improved in patients with and without cataplexy. More clinical trials are needed to analyze the efficacy of solriamfetol on cataplexy. The effect of solriamfetol in EDS seems to be conclusive.

show abstract